Company Overview

ZY.US
/’zī-es/

ZYUS is inspired by science. Born from the abstraction of ‘science’ and ‘zygote’ (the fusion of two cells), we represent the beginning of life and the importance of improving quality of life. We believe in taking a forward, collaborative approach and place high value in our teamwork, partnerships and commitment to the broader ‘us' - society. We believe that together, we can bring phyto-therapeutics to the global medical market.

About ZYUS Life Sciences

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and innovative exempt market therapeutics. Through clinical research, ZYUS is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, ZYUS is dedicated to delivering high quality, cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market.

The ZYUS vision is to elevate cannabinoid-based therapeutics as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives around the world.

ZYUS: Advancing the Science of Well-Being.

Our Approach

Pharmaceutical Drug Product Candidates

The development, protection, and regulatory approval of our pharmaceutical drug product candidates from authorities such as the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Health Canada. Followed by commercialization of these proprietary drug products for use in treatment of specific diseases and indications.

Exempt Medical Market Products

While the primary focus is on the clinical development of ZYUS' regulatory approved pharmaceutical drug product candidates, we also are engaged in the commercialization of our exempt market therapeutics such as cannabinoid oils, softgel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.

Brent Zettl, ZYUS President & CEO

Prior to becoming the President and CEO of ZYUS, Mr. Zettl was the co-founder of Prairie Plant Systems Inc. in 1988 (“PPS”), CanniMed Ltd. in 2013 and their parent company, CanniMed Therapeutics Inc., in 2016. PPS and CanniMed Ltd. became the first two licensed producers of cannabis under the Marihuana for Medical Purposes Regulations and were the exclusive suppliers of medical cannabis to Health Canada from 2000 to 2014. In March 2018, CanniMed Therapeutics Inc. was acquired by Aurora Cannabis Inc. for approximately CAD$1.2 billion, the largest acquisition of a cannabis company at the time.

With over 20 years of experience pioneering the medical cannabis industry, ZYUS has a vision to reimagine the potential of cannabinoids - in pursuit of transformational impact on patients' lives.